PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kahnert, K.* ; Alter, P.* ; Young, D.M.* ; Lucke, T.* ; Heinrich, J.* ; Huber, R.M.* ; Behr, J.* ; Wacker, M. ; Biertz, F.* ; Watz, H.* ; Bals, R.* ; Welte, T.* ; Wirtz, H.* ; Herth, F.* ; Vestbo, J.* ; Wouters, E.F.* ; Vogelmeier, C.F.* ; Jörres, R.A.*

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Respir. Med. 134, 79-85 (2018)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Introduction: The COPD classification proposed by the Global Initiative for Obstructive Lung Disease was recently revised, and the A to D grouping is now based on symptoms and exacerbations only. Potential associations with comorbidities have not been assessed so far. Thus the aim of the present study was to determine the relationship between the revised (2017) GOLD groups A-D and major comorbidities. Methods: We used baseline data from the COPD cohort COSYCONET. Comorbidities were identified from patient self-reports and disease-specific medication: gastrointestinal disorders, asthma, sleep apnea, hyperuricemia, hyperlipidemia, diabetes, osteoporosis, mental disorders, heart failure, hypertension, coronary artery disease. The A-D groups were based on either the COPD Assessment Test or the modified Medical Research Council scale. Exacerbations were also categorized as per GOLD recommendations. Results: Data from 2228 patients were analyzed. Using GOLD group A as a reference, group D was associated with nearly all comorbidities, followed by group B and C. When groups A-D were dichotomized as AC vs. BD (symptoms) and AB vs. CD (exacerbations), all comorbidities correlated with symptoms and/or exacerbations. This was true for both mMRC- and CAT-based categorizations. Conclusions: These findings suggest that the recently modified GOLD categorization is clinically relevant beyond being purely an assessment of symptoms and exacerbations. As the A-D groups correlated with the risk of important comorbidities, with some differences in terms of the correlation with symptoms and exacerbations, the findings underline the importance of identifying comorbidities in COPD, particularly in non-responders to therapy who have high symptoms and/or exacerbation rates.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.230
1.169
32
30
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Copd ; Gold Categorization ; Comorbidities; Obstructive Pulmonary-disease; Heart-failure; Acute Exacerbations; Lung-function; Mortality; Population; Definition; Prediction; Management; Markers
Sprache
Veröffentlichungsjahr 2018
Prepublished im Jahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 0954-6111
e-ISSN 1532-3064
Zeitschrift Respiratory Medicine
Quellenangaben Band: 134, Heft: , Seiten: 79-85 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Health Economics and Health Care Management (IGM)
POF Topic(s) 80000 - German Center for Lung Research
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-501800-533
DOI 10.1016/j.rmed.2017.12.003
WOS ID WOS:000425285300012
Scopus ID 85042259422
PubMed ID 29413512
Erfassungsdatum 2018-02-09
[➜Korrektur melden]